Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Heart attack patients treated beyond maximum recommended time have increased mortality: Study

An examination of the treatment received by patients with myocardial infarction (heart attack) at 80 hospitals in Quebec indicates that those who received either primary percutaneous coronary intervention (PPCI; such as angioplasty) or fibrinolysis (administration of medication to dissolve blood clots) beyond the times recommended in international guidelines had a significantly increased risk of death within 30 days, along with an increased risk of the combined outcome of death or readmission for heart attack or heart failure at one year, according to a study in the June 2 issue of JAMA.

2 Jun 2010

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense™, Inc., a diagnostic device company that has been in stealth mode for the past two years, today unveiled the first portable point-of-care Prothrombin Time/International Normalized Ratio (PT/INR) analyzer to directly detect blood clotting time for patients stabilized on oral anti-coagulation medications such as Coumadin® or warfarin.

2 Jun 2010

Targeted Genetics reports net income of $1.8M for fourth-quarter 2009 compared to net loss of $10.8M in 2008

Targeted Genetics Corporation today announced its financial results for the fourth quarter and full year ended December 31, 2009.

1 Jun 2010

FAIR-HF study: Ferinject improves renal function in patients with CHF and iron deficiency

Results of a subanalysis from the FAIR-HF study demonstrate that correcting iron deficiency with Ferinject (ferric carboxymaltose) can improve renal function in chronic heart failure patients. Ferinject is an intravenous iron product used to treat iron deficiency and iron deficiency anaemia.

From CSL Ltd 31 May 2010

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICAR® show improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy.

31 May 2010

Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010

Targeted Genetics Corporation announced that its partner, Celladon Corporation, presented full data today that show the first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

31 May 2010

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Bioheart, Inc., announced today plans for establishing two Centers of Excellence in the Middle East to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease. Dr. Karl E. Groth, Chairman and CEO, and Peggy A. Farley, Chief Operating and Financial Officer, are now in that region holding discussions and performing site inspections.

29 May 2010

Patients Medical offers innovative stroke treatments to live longer, healthier life

Patients Medical, a leading integrative medical center in New York City, offers innovative stroke treatments such as hyperbaric oxygen therapy, acupuncture, diet therapy and customized intravenous nutrition drips. Daniel Silverstein, MD, holistic physician, recommends focusing on prevention to avoid a stroke and to live a longer, healthier life.

29 May 2010

Cardiac biomarkers help nephrologists manage fluid overload in dialysis patients: Study

Nephrologists must consider fluid overload effects when prescribing dialysis, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology. The fluid overload biomarker, N-terminal pro-brain-type natriuretic peptide, previously known as a "cardiac biomarker" in dialysis patients, is an important component of managing patients with kidney disease.

28 May 2010

BG Medicine announces data presentations on galectin-3 at Heart Failure Congress 2010

BG Medicine, Inc., a U.S. based, privately-held biomarker discovery and in vitro diagnostics company, announced today that there will be several data presentations regarding galectin-3 at the Heart Failure Congress 2010, the annual scientific meeting of the Heart Failure Association of the European Society of Cardiology, to be held in Berlin, Germany, on May 29th through June 1st. BG Medicine has developed and applied for FDA clearance of an in vitro diagnostic test to measure galectin-3 levels in plasma or serum.

28 May 2010

State-of-the-art heart pump lowers risk for infection in end-stage cardiac patients: Researchers

A state-of-the-art heart pump recently approved for use in end-stage cardiac patients has a significantly lower risk for infection than an earlier model of the device, according to researchers at Henry Ford Hospital in Detroit.

28 May 2010

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.

28 May 2010

HeartMate II left ventricular assist device also improves right side heart function

A state-of-the-art heart pump, designed to maintain a continuous flow of blood in end-stage cardiac patients with damage to the left side of the heart, also improves function on the right side of the heart, according to researchers at Henry Ford Hospital's Heart and Vascular Institute.

27 May 2010

Pfizer plans recruitment halt to EMPHASIS-HF trial

Pfizer Inc. announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules.

27 May 2010

New clinical data for CoreValve transcatheter aortic valve replacement system presented at EuroPCR

New clinical data presented today at EuroPCR demonstrate positive long-term performance and durability for the CoreValve transcatheter aortic valve replacement system from Medtronic, Inc. Two-year results from the pivotal 18-French CoreValve multicenter prospective study provide important additional evidence supporting wider use of the world's market-leading transcatheter aortic valve.

26 May 2010

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration approval of VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.

26 May 2010

SunTech Medical's clinical-grade blood pressure technology selected for new Portable PFS

SunTech Medical, a leading manufacturer of blood pressure monitors and OEM non-invasive blood pressure modules, is pleased to announce the selection of their clinical-grade blood pressure technology for the new Portable Pulmonary Function System by Damec.

26 May 2010

EIRMC, West Valley Medical Center to continue to serve Humana's Medicare Advantage members

Eastern Idaho Regional Medical Center (EIRMC), a full-service regional medical center in Idaho Falls, and West Valley Medical Center, a community hospital in Caldwell, will continue to provide in-network medical care to all Medicare Advantage members enrolled in plans offered by Humana, under terms of a renewal agreement announced today.

26 May 2010

t2c001 product obtains certificate under EMA regulations for ATMPs

t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the quality of its lead product t2c001 has been certified by the European Medicines Agency.

25 May 2010

Researchers explore impact of asymptomatic LV dysfunction in vascular surgery patients

Symptomatic heart failure prior to surgery is routinely acknowledged as a risk factor for adverse outcomes for both cardiac and non-cardiac surgeries. In a new study published in the June Anesthesiology, researchers delve further into the implications of cardiac problems on postoperative outcomes, exploring preoperative diagnosis and impact of asymptomatic left ventricular dysfunction in vascular surgery patients.

25 May 2010

Heart Failure News and Research

Further Reading

Heart attack patients treated beyond maximum recommended time have increased mortality: Study

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

Targeted Genetics reports net income of $1.8M for fourth-quarter 2009 compared to net loss of $10.8M in 2008

FAIR-HF study: Ferinject improves renal function in patients with CHF and iron deficiency

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Patients Medical offers innovative stroke treatments to live longer, healthier life

Cardiac biomarkers help nephrologists manage fluid overload in dialysis patients: Study

BG Medicine announces data presentations on galectin-3 at Heart Failure Congress 2010

State-of-the-art heart pump lowers risk for infection in end-stage cardiac patients: Researchers

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

HeartMate II left ventricular assist device also improves right side heart function

Pfizer plans recruitment halt to EMPHASIS-HF trial

New clinical data for CoreValve transcatheter aortic valve replacement system presented at EuroPCR

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

SunTech Medical's clinical-grade blood pressure technology selected for new Portable PFS

EIRMC, West Valley Medical Center to continue to serve Humana's Medicare Advantage members

t2c001 product obtains certificate under EMA regulations for ATMPs

Researchers explore impact of asymptomatic LV dysfunction in vascular surgery patients

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News